<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">medalphabet-374</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Неинвазивные электрофизиологические показатели и высокочувствительный тропонин в стратификации риска фатальных событий у больных с дилатационной кардиомиопатией</article-title><trans-title-group xml:lang="en"><trans-title>Non-invasive electrophysiologicalparameters and high-sensitive troponin in risk stratification of fatal events in patients with dilated cardiomyopathy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Седов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sedov</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Царегородцев</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsaregorodtsev</surname><given-names>D. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сулимов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sulimov</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России (Сеченовский университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First Moscow State Medical University n.a. I. M. Sechenov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2017</year></pub-date><volume>3</volume><issue>39</issue><issue-title>Современная функциональная диагностика</issue-title><fpage>8</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Седов А.В., Царегородцев Д.А., Сулимов В.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Седов А.В., Царегородцев Д.А., Сулимов В.А.</copyright-holder><copyright-holder xml:lang="en">Sedov A.V., Tsaregorodtsev D.A., Sulimov V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/374">https://www.med-alphabet.com/jour/article/view/374</self-uri><abstract><p>Дилатационная кардиомиопатия (ДКМП) в настоящее время, несмотря на внедрение современных методик лечения в т.ч. интервенционных, остается заболеванием с неблагоприятным прогнозом. Цель: изучить особенности и прогностическое значения неинвазивных электрофизиологических предикторов внезапной сердечной смерти - турбулентности ритма сердца (ТРС), вариабельности ритма сердца (ВРС), мощности замедления (DC), мощности ускорения ритма сердца (AC) и высокочувствительного тропонина (ВЧТ) у больных с дилатационной кардиомиопатией (ДКМП). Материал и методы: в течение четырех лет проводилось наблюдение за 54 пациентами с ДКМП и синусовым ритмом в возрасте 42 [30; 58] лет (36 мужчин) и контрольной группой - 54 человека без сердечно-сосудистой патологии (32 мужчины, средний возраст 47 [27; 64] лет). Исходно проводили холтеровское мониторирование ЭКГ (ХМ) с оценкой ВРС, ТРС, DC, AC, эхокардиографию. У 30 пациентов с ДКМП и 14 лицам без сердечно-сосудистой патологии выполнялось биохимическое исследование крови с определением концентрации ВЧТ. Средняя фракция выброса (ФВ) в основной группе составила 32 [22; 38]%, признаки ХСН выявлены у 93 % больных. Пациенты с ДКМП получали стандартную терапию хронической сердечной недостаточности (ХСН); частота имплантаций кардиовертеров-дефибрилляторов (ИКД) составила 18,5 %. Результаты: больные с ДКМП отличались от контрольной группы достоверно более низкими значениями SDNN, pNN50, DC, TO, TS, более высокими значениями AC и более высокой концентрацией ВЧТ. В течение четырех лет зарегистрирована одна ВСС, от прогрессирования ХСН умерли семь пациентов, наблюдался один адекватный шок у больного с ИКД (всего девять фатальных событий). Пациенты с фатальными событиями по сравнению с выжившими имели более низкую ФВ, ВРС, DC, большие конечный диастолический объем, класс ХСН, АС, в утренние часы, число эпизодов неустойчивой желудочковой тахикардии (нЖТ), однако не характеризовались более высокими показателями ВЧТ. При однофакторном анализе достоверно увеличивали риск фатальных событий (в порядке убывания значимости): ФВ (отношение шансов [ОШ] 32), SDNN (ОШ 21), DC (ОШ 9), AC (ОШ 7), pNN50 (ОШ 6), нЖТ (ОШ 5,2; p = 0,05). При многофакторном анализе единственным независимым предиктором фатальных событий явилось снижение ФВ левого желудочка менее 26 % (чувствительность 80 %о, специфичность 90 %). Заключение: неинвазивные электрофизиологические предикторы АС, DC, ВРС могут использоваться как дополнительные методы стратификации риска фатальных событий у больных с дилатационной кардиомиопатией. При этом определение концентрации ВЧТ нецелесообразно. Вместе с тем единственным независимым предиктором неблагоприятного исхода в течение четырех лет является ФВ левого желудочка. Снижение ФВ менее 26 % увеличивает риск фатальных событий в 32 раза.</p></abstract><trans-abstract xml:lang="en"><p>Dilated cardiomyopathy (DCM) remains a disease with a poor prognosis. The improvement of the risk stratification for the fatal events, especially sudden cardiac death (SCD) to introduce preventive measures timely is an unmet need. Previously proposed non-invasive electrophysiological predictors - heart rate turbulence (HRT) and variability (HRV), deceleration (DC), acceleration (AC) capacity and high-sensitivity troponin (hs-Tn) - have not been evaluated in DCM. Material and methods. We enrolled 54 patients with DCM and sinus rhythm aged 42 [30; 58] years (36 males) and 54 people without cardiovascular diseases (32 males, median age 47 [27; 64] years) in the control group. The follow-up period was 4 years. At baseline, we performed ambulatory (Holter) ECG monitoring (AECG) with the assessment of HRV, HRT, DC, AC, echocardiography. In 30 patients with DCM and 14 persons without cardiovascular pathology was carried out biochemical blood analysis with determination of the concentration of hs-Tn. Patients received standard treatment for CHF, 18.5 % of patients underwent implantations of cardioverter defibrillators (ICDs). Results. The median LVEF in the study group was 32 % [22; 38]. CHF signs were reported in 93 % of patients. Patients with DCM differed from the control group, significantly lower values of SDNN, pNN 50, DC, TO, TS, and higher values of AC in early morning hours and a higher concentration of high-sensitivity troponin. During the 4 years, one SCD was reported, 7 patients died due to CHF progression, and one adequate shock in a patient with ICD was detected (a total of 9 fatal events). Patients with fatal events compared to survivors had lower EF, VRS, DC, large end-diastolic volume, the class CHF, ACE in early morning hours, the number of episodes of unstable ventricular tachycardia (NHT), however, was not characterized by higher levels of hs-Tn. In univariate analysis, the following predictors significantly increased the risk of fatal events (in order of importance): LVEF (Odds Ratio (OR) 32), SDNN (OR21), DC (OR 9), AC (OR 7'), pNN50 (OR6), nVT (OR5.2; p = 0.05). In multivariate analysis, LVEF &lt; 26 % was the only independent predictor of fatal events (sensitivity 80 %, specificity 90 %). Conclusions. Non-invasive electrophysiological predictors of AC, DC, HRV may be used as additional methods of risk stratification of fatal events in patients with dilated cardiomyopathy. The determination of the concentration of hs-Tn is inappropriate. However, the only independent predictor of adverse outcome during 4 years is the PV of the left ventricle. The decrease in EF less than 26 % increases the risk of fatal events in 32 times.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>дилатационная кардиомиопатия</kwd><kwd>внезапная сердечная смерть</kwd><kwd>турбулентность ритма сердца</kwd><kwd>мощность замедления</kwd><kwd>мощность ускорения</kwd><kwd>вариабельность ритма сердца</kwd><kwd>холтеровское мониторирование</kwd><kwd>фракция выброса</kwd><kwd>высокочувствительный тропонин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>dilated cardiomyopathy</kwd><kwd>sudden cardiac death</kwd><kwd>a turbulence of heart rhythm</kwd><kwd>deceleration capacity</kwd><kwd>acceleration capacity</kwd><kwd>heart rate variability</kwd><kwd>Holter monitoring</kwd><kwd>ejection fraction</kwd><kwd>high-sensitivity troponin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Coughlin SS, Myers L, Michaels RK. What explains black-white differences in survival in idiopathic dilated cardiomyopathy? The Washington, DC, Dilated Cardiomyopathy Study. J Natl Med Assoc 1997; 89: 277-82.</mixed-citation><mixed-citation xml:lang="en">Coughlin SS, Myers L, Michaels RK. What explains black-white differences in survival in idiopathic dilated cardiomyopathy? The Washington, DC, Dilated Cardiomyopathy Study. J Natl Med Assoc 1997; 89: 277-82.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Di LA, Secoli G, Perkan A, et al. Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group. Br Heart J 1994; 72: S46-S51.</mixed-citation><mixed-citation xml:lang="en">Di LA, Secoli G, Perkan A, et al. Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group. Br Heart J 1994; 72: S46-S51.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death European Heart Journal. 2015; doi/10.1093/ eurheartj/ehv316: 35-7.</mixed-citation><mixed-citation xml:lang="en">ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death European Heart Journal. 2015; doi/10.1093/ eurheartj/ehv316: 35-7.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet. 2006; 367: 1674-81.</mixed-citation><mixed-citation xml:lang="en">Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet. 2006; 367: 1674-81.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med. 1971; 285: 877-83.</mixed-citation><mixed-citation xml:lang="en">Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med. 1971; 285: 877-83.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tsaregorodtsev D. A., Bukia I. R., Sulimov V. A., Leont'eva I.V., Makarova V.A. Turbulence heart rate and microvolt T-wave alternans as a marker of risk for sudden cardiac death in patients with hypertrophic cardiomyopathy, Cardiology No. 9, 2013, p. 40-46.</mixed-citation><mixed-citation xml:lang="en">Tsaregorodtsev D. A., Bukia I. R., Sulimov V. A., Leont'eva I.V., Makarova V.A. Turbulence heart rate and microvolt T-wave alternans as a marker of risk for sudden cardiac death in patients with hypertrophic cardiomyopathy, Cardiology No. 9, 2013, p. 40-46.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Okisheva E, Tsaregorodtsev D, Sulimov V. Combined ECG-based risk stratification for sudden cardiac death in patients after myocardial infarction: 5-year data. European Heart Journal 2015, 36 (suppl 1), p. 808.</mixed-citation><mixed-citation xml:lang="en">Okisheva E, Tsaregorodtsev D, Sulimov V. Combined ECG-based risk stratification for sudden cardiac death in patients after myocardial infarction: 5-year data. European Heart Journal 2015, 36 (suppl 1), p. 808.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016; 375 (13): 1221-30.</mixed-citation><mixed-citation xml:lang="en">Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016; 375 (13): 1221-30.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Apple F. S. A new season for cardiac troponin assays: It's time to keep a scorecard. Clin. Chem. 2009; 55: 1303-1306.</mixed-citation><mixed-citation xml:lang="en">Apple F. S. A new season for cardiac troponin assays: It's time to keep a scorecard. Clin. Chem. 2009; 55: 1303-1306.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor MR, Carniel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis 2006; 1: 27.</mixed-citation><mixed-citation xml:lang="en">Taylor MR, Carniel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis 2006; 1: 27.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
